Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models.

MLA

Barutello, Giuseppina, et al. “Immunotherapy against the Cystine/Glutamate Antiporter XCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models.” Biomedicines, vol. 10, no. 11, Nov. 2022, p. 2843. EBSCOhost, https://doi.org/10.3390/biomedicines10112843.

APA

Barutello, G., Di Lorenzo, A., Gasparetto, A., Galiazzi, C., Bolli, E., Conti, L., & Cavallo, F. (2022). Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models. Biomedicines, 10(11), 2843. https://doi.org/10.3390/biomedicines10112843

Chicago

Barutello, Giuseppina, Antonino Di Lorenzo, Alessandro Gasparetto, Chiara Galiazzi, Elisabetta Bolli, Laura Conti, and Federica Cavallo. 2022. “Immunotherapy against the Cystine/Glutamate Antiporter XCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models.” Biomedicines 10 (11): 2843. doi:10.3390/biomedicines10112843.